Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia

Haematologica

Volumn 99, Issue 5, 2014, Pages

  Gassner, Franz J ^a   Zaborsky, Nadja ^a   Neureiter, Daniel ^a   Huemer, Michael ^a   Melchardt, Thomas ^a   Egle, Alexander ^a   Rebhandl, Stefan ^a   Catakovic, Kemal ^a   Hartmann, Tanja N ^a   Greil, Richard ^a   Geisberger, Roland ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Chronic lymphocytic leukemia; Lenalidomide; T cell imhibitory receptors

Indexed keywords

CD57 ANTIGEN; FLUDARABINE; LENALIDOMIDE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR 2B4; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN RECEPTOR; THALIDOMIDE;

CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOSURVEILLANCE; LETTER; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INDUCTION CHEMOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM;

ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; THALIDOMIDE;

EID: 84899722959     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.098459     Document Type: Letter

References (15)

1. Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat Rev Clin Oncol. 2009; 6(7): 405-18.
2. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukaemia. Br Med Bull. 2008; 87: 49-62.
3. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7): 1412-21.
4. Nunes CT, Wong R, Mason M, Fegan C, Man S, Pepper C. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4: CD8 ratios and disease progression. Clin Cancer Res. 2012; 18(3): 678-87.
5. Brusa D, Serra S, Coscia M, Rossi D, D'Arena G, Laurenti L, et al. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6): 953-63.
6. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008; 118(7): 2427-37.
7. Youngblood B, Wherry EJ, Ahmed R. Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr Opin HIV AIDS. 2012; 7(1): 50-7.
8. Strioga M, Pasukoniene V, Characiejus D. CD8(+) CD28(-) and CD8(+) CD57(+) T cells and their role in health and disease. Immunology. 2011; 134(1): 17-32.
9. Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57(+)CD4(+) T cells and their association with HIV-1-induced T cell dysfunction. J Immunol. 2005; 175(12): 8415-23.
10. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCVSpecific CD8+T Cells Is Linked to Antigen Recognition and T Cell Differentiation. PLoS Pathog. 2010; 6(6): e1000947.
11. Egle A, Steurer M, Gassner F, Geisberger R, Melchardt T, Weiss L, et al. A Combination of Fludarabine/Rituximab with Escalating Doses of Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL): The REVLIRIT CLL5 AGMT Phase I/II Study, Clinical and Exploratory Analyses of Induction Results. Blood. 2011; 118(21): 135-6.
12. Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, et al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol. 2009; 155(3): 423-32.
13. Gassner FJ, Weiss L, Geisberger R, Hofbauer JP, Egle A, Hartmann TN, et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother. 2011; 60(1): 75-85.
14. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, et al. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013; 121(20): 4137-41.
15. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005; 25(21): 9543-53.